Foto del docente

Elena Zamagni

Associate Professor

Department of Experimental, Diagnostic and Specialty Medicine - DIMES

Academic discipline: MED/15 Blood Diseases

Publications

Martello M.; Poletti A.; Borsi E.; Solli V.; Dozza L.; Barbato S.; Zamagni E.; Tacchetti P.; Pantani L.; Mancuso K.; Vigliotta I.; Rizzello I.; Rocchi S.; Armuzzi S.; Testoni N.; Marzocchi G.; Martinelli G.; Cavo M.; Terragna C., Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma, «BLOOD CANCER JOURNAL», 2022, 12, Article number: 15 , pp. 15 - 15 [Scientific article]Open Access

Rocchi S.; Tacchetti P.; Pantani L.; Mancuso K.; Rizzello I.; di Giovanni Bezzi C.; Scalese M.; Dozza L.; Marzocchi G.; Martello M.; Barila G.; Antonioli E.; Staderini M.; Buda G.; Petrini M.; Cea M.; Quaresima M.; Furlan A.; Bonalumi A.; Cavo M.; Zamagni E., A real-world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed/refractory multiple myeloma, «HEMATOLOGICAL ONCOLOGY», 2021, 39, pp. 41 - 50 [Scientific article]

Gay F.; Musto P.; Rota-Scalabrini D.; Bertamini L.; Belotti A.; Galli M.; Offidani M.; Zamagni E.; Ledda A.; Grasso M.; Ballanti S.; Spadano A.; Cea M.; Patriarca F.; D'Agostino M.; Capra A.; Giuliani N.; de Fabritiis P.; Aquino S.; Palmas A.; Gamberi B.; Zambello R.; Petrucci M.T.; Corradini P.; Cavo M.; Boccadoro M., Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial, «THE LANCET ONCOLOGY», 2021, 22, pp. 1705 - 1720 [Scientific article]

Sonneveld P.; Dimopoulos M.A.; Beksac M.; van der Holt B.; Aquino S.; Ludwig H.; Zweegman S.; Zander T.; Zamagni E.; Wester R.; Hajek R.; Pantani L.; Dozza L.; Gay F.; Cafro A.; De Rosa L.; Morelli A.; Gregersen H.; Gulbrandsen N.; Cornelisse P.; Troia R.; Oliva S.; van de Velden V.; Wu K.; Ypma P.F.; Bos G.; Levin M.-D.; Pour L.; Driessen C.; Broijl A.; Croockewit A.; Minnema M.C.; Waage A.; Hveding C.; van de Donk N.W.C.J.; Offidani M.; Palumbo G.A.; Spencer A.; Boccadoro M.; Cavo M., Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma, «JOURNAL OF CLINICAL ONCOLOGY», 2021, 39, pp. 3613 - 3622 [Scientific article]

Mina R.; Bonello F.; Gay F.; Zamagni E.; Boccadoro M., Daratumumab-Based Therapy for IgM Multiple Myeloma With Hyperviscosity Syndrome: A Case Report, «CLINICAL LYMPHOMA MYELOMA & LEUKEMIA», 2021, 21, pp. e21 - e24 [Scientific article]

Gentile M.; Specchia G.; Derudas D.; Galli M.; Botta C.; Rocco S.; Conticello C.; Califano C.; Giuliani N.; Mangiacavalli S.; Attingenti E.; Lombardo A.; Brunori M.; Rossi E.; Antonioli E.; Ria R.; Zambello R.; Di Renzo N.; Mele G.; Marcacci G.; Musto P.; Capalbo S.; Cascavilla N.; Cerchione C.; Belotti A.; Criscuolo C.; Uccello G.; Curci P.; Vigna E.; Fraticelli V.; Vincelli D.; Bonalumi A.; Siniscalchi A.; Stocchi R.; Martino M.; Ballanti S.; Gangemi D.; Gagliardi A.; Gamberi B.; Pompa A.; Recchia A.G.; Tripepi G.; Pitino A.; Frigeri F.; Consoli U.; Bringhen S.; Zamagni E.; Patriarca F.; De Stefano V.; Di Raimondo F.; Palmieri S.; Petrucci M.T.; Offidani M.; Boccadoro M.; Cavo M.; Morabito F., Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials, «HAEMATOLOGICA», 2021, 106, pp. 291 - 294 [Scientific article]

Tacchetti P.; Rocchi S.; Barbato S.; Zamagni E.; Pantani L.; Mancuso K.; Rizzello I.; Cavo M., Emerging and current treatment combinations for transplant-ineligible multiple myeloma patients, «EXPERT REVIEW OF HEMATOLOGY», 2021, 14, pp. 1085 - 1098 [Scientific article]

Cavo M.; Tacchetti P.; Zamagni E., Expanding CD38-targeting triplets for relapsed or refractory multiple myeloma, «THE LANCET», 2021, 397, pp. 2311 - 2313 [Scientific article]

Rosinol L.; Beksac M.; Zamagni E.; Van de Donk N.W.C.J.; Anderson K.C.; Badros A.; Caers J.; Cavo M.; Dimopoulos M.-A.; Dispenzieri A.; Einsele H.; Engelhardt M.; Fernandez de Larrea C.; Gahrton G.; Gay F.; Hajek R.; Hungria V.; Jurczyszyn A.; Kroger N.; Kyle R.A.; Leal da Costa F.; Leleu X.; Lentzsch S.; Mateos M.V.; Merlini G.; Mohty M.; Moreau P.; Rasche L.; Reece D.; Sezer O.; Sonneveld P.; Usmani S.Z.; Vanderkerken K.; Vesole D.H.; Waage A.; Zweegman S.; Richardson P.G.; Blade J., Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations, «BRITISH JOURNAL OF HAEMATOLOGY», 2021, 194, pp. 496 - 507 [Scientific article]

Zamagni, Elena; Barbato, Simona; Cavo, Michele, How I Treat High-risk Multiple Myeloma, «BLOOD», 2021, blood.2020008733, pp. N/A - N/A [Scientific article]

Anderson K.C.; Auclair D.; Adam S.J.; Agarwal A.; Anderson M.; Avet-Loiseau H.; Bustoros M.; Chapman J.; Connors D.E.; Dash A.; Bacco A.D.; Du L.; Facon T.; Flores-Montero J.; Gay F.; Ghobrial I.M.; Gormley N.J.; Gupta I.; Higley H.; Hillengass J.; Kanapuru B.; Kazandjian D.; Kelloff G.J.; Kirsch I.R.; Kremer B.; Landgren O.; Lightbody E.; Lomas O.C.; Lonial S.; Mateos M.-V.; de Oca R.M.; Mukundan L.; Munshi N.C.; Odonnell E.K.; Orfao A.; Paiva B.; Patel R.; Pugh T.J.; Ramasamy K.; Ray J.; Roshal M.; Ross J.A.; Sigman C.C.; Thoren K.L.; Trudel S.; Ulaner G.; Valente N.; Weiss B.M.; Zamagni E.; Kumar S.K., Minimal residual disease in Myeloma: Application for clinical care and new drug registration, «CLINICAL CANCER RESEARCH», 2021, 27, pp. 5195 - 5212 [Scientific article]

Jamet B.; Morvan L.; Nanni C.; Michaud A.-V.; Bailly C.; Chauvie S.; Moreau P.; Touzeau C.; Zamagni E.; Bodet-Milin C.; Kraeber-Bodere F.; Mateus D.; Carlier T., Random survival forest to predict transplant-eligible newly diagnosed multiple myeloma outcome including FDG-PET radiomics: a combined analysis of two independent prospective European trials, «EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING», 2021, 48, pp. 1005 - 1015 [Scientific article]

Zamagni E.; Dhanasiri S.; Ghale A.; Moore A.; Roussel M., Real-world analysis of patient characteristics, treatment outcomes, and healthcare resource utilization across Europe in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation who received lenalidomide- or bortezomib-based regimens, «LEUKEMIA & LYMPHOMA», 2021, 62, pp. 2492 - 2501 [Scientific article]

Zamagni E.; Nanni C.; Dozza L.; Carlier T.; Bailly C.; Tacchetti P.; Versari A.; Chauvie S.; Gallamini A.; Gamberi B.; Caillot D.; Patriarca F.; Macro M.; Boccadoro M.; Garderet L.; Barbato S.; Fanti S.; Perrot A.; Gay F.; Sonneveld P.; Karlin L.; Cavo M.; Bodet-Milin C.; Moreau P.; Kraeber-Bodere F., Standardization of 18F-FDG-PET/CT According to Deauville Criteria for Metabolic Complete Response Definition in Newly Diagnosed Multiple Myeloma, «JOURNAL OF CLINICAL ONCOLOGY», 2021, 39, pp. 116 - 125 [Scientific article]

Rizzello I.; Cavo M.; Dozza L.; Rivolti E.; Petrucci M.T.; De Stefano V.; Antonioli E.; Tosi P.; D'Agostino M.; More S.; Gozzetti A.; Cea M.; Barbato S.; Tacchetti P.; Pantani L.; Mancuso K.; Rocchi S.; De Cicco G.; Fusco A.; Zamagni E., Subcutaneous bortezomib-containing regimens as up-front treatment of newly diagnosed transplant-eligible multiple myeloma patients: a retrospective, non-interventional observational study, «LEUKEMIA & LYMPHOMA», 2021, 62, pp. 1897 - 1906 [Scientific article]